Comparison of intravitreal preservative-free triamcinolone versus posterior sub-tenon triamcinolone acetonide injection for bevacizumab-resistant diabetic macular edema

Table 2 Changes in central macular thickness, best-corrected visual acuity, and intraocular pressure observed during the 3-month follow-up period in each group: intravitreal and sub-Tenon’s capsule triamcinolone acetonide injection

	IVTA	P value	STTA	P value	Differences between IVTA and STTA P value
CMT (µm)
Baseline	400.2 ± 144.42		446.65 ± 120.74
1 month	261.4 ± 108.18	< 0.001*	349.9 ± 120.15	0.005*	0.194
2 months	260.45 ± 108.20	< 0.001*	379 ± 124.11	0.035*	0.168
3 months	288.35 ± 151.74	0.01*	382.9 ± 113.58	0.009*	0.903
BCVA (logMAR)
Baseline	0.75 ± 0.55		0.6 ± 0.36
1 month	0.6 ± 0.45	0.036*	0.53 ± 0.35	0.016*	0.546
2 months	0.645 ± 0.45	0.199	0.54 ± 0.33	0.076	0.900
3 months	0.625 ± 0.50	0.089	0.54 ± 0.35	0.094	0.787
IOP (mmHg)
Baseline	17.2 ± 2.75		17.45 ± 2.41
1 month	17.85 ± 2.9	0.129	18.10 ± 2.82	0.106	0.754
2 months	17.55 ± 3.38	0.721	17.80 ± 2.35	0.384	0.575
3 months	16.95 ± 2.39	0.981	17.55 ± 2.18	0.872	0.342

BCVA, best-corrected visual acuity; CMT, central macular thickness; IOP, intraocular pressure; IVTA, intravitreal triamcinolone acetonide injection; STTA, Sub-tenon capsule triamcinolone acetonide injection
* p < 0.05

ISSN: 1471-2415